Ozden Eriz, Turgut Ahmet Tuncay, Talas Halit, Yaman Onder, Göğüş Orhan
Department of Urology, Ankara University, School Of Medicine, Camlitepe mah. Taskent str no 35/8 Kurtulus, Cankaya, Ankara, Turkey.
Int Urol Nephrol. 2007;39(2):525-9. doi: 10.1007/s11255-006-9078-5. Epub 2007 Feb 15.
To evaluate if volume or any of the three dimensions of prostate influences cancer detection rate by 12-core transrectal ultrasound (TRUS) guided prostate biopsy.
We have searched our database for patients who underwent 12 core TRUS guided prostate biopsy with PSA values between 4.0 and 9.9 ng/ml, benign digital exam and no suspicious lesions at TRUS. The measurements of three dimensions and volume of the prostate of 99 patients were correlated with cancer detection rates of biopsy.
There were no statistically significant differences between patients with prostate cancer or with benign histopathologic result for mean age, PSA and % PSA. Patients without cancer had a significantly higher mean prostate volume (58.88 cc) than patients with cancer (48.85 cc) (P = 0.038). A volume of 48.5 cc was determined as a cut-off value above which cancer detection rate decreases. Of the three dimensions, only the difference for the craniocaudal dimension between benign and malignant groups was marginally significant (P = 0.052).
With 12 core biopsy, cancer detection rate is lower in patients with prostates larger than 48.5 cc. Further studies comparing biopsy results with prostatectomy specimens can clarify whether these results necessitates higher number of cores for such patients.
评估前列腺的体积或三个维度中的任何一个是否会影响经直肠超声(TRUS)引导下12针前列腺穿刺活检的癌症检出率。
我们在数据库中搜索了接受12针TRUS引导下前列腺穿刺活检的患者,这些患者的前列腺特异性抗原(PSA)值在4.0至9.9 ng/ml之间,直肠指检为良性,且TRUS检查未发现可疑病变。对99例患者的前列腺三个维度及体积的测量结果与穿刺活检的癌症检出率进行相关性分析。
前列腺癌患者与组织病理学结果为良性的患者在平均年龄、PSA及PSA百分比方面无统计学显著差异。无癌症患者的平均前列腺体积(58.88立方厘米)显著高于癌症患者(48.85立方厘米)(P = 0.038)。确定48.5立方厘米为一个临界值,超过该值癌症检出率会降低。在三个维度中,只有良性组和恶性组之间的头脚维度差异具有边缘显著性(P = 0.052)。
对于12针穿刺活检,前列腺体积大于48.5立方厘米的患者癌症检出率较低。进一步将穿刺活检结果与前列腺切除标本进行比较的研究可以阐明这些结果是否需要为此类患者增加穿刺针数。